<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0005">
 <label>Table 1</label>
 <caption>
  <p>Clinical phase vaccine candidates for COVID-19 [
   <xref rid="bib0200" ref-type="bibr">40</xref>].
  </p>
 </caption>
 <alt-text id="at0050">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Candidate</th>
    <th align="left">Vaccine characteristic</th>
    <th align="left">Lead developer</th>
    <th align="left">status</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">mRNA-1273</td>
    <td align="left">LNP-encapsulated mRNA vaccine encoding S protein</td>
    <td align="left">Moderna</td>
    <td align="left">Phase I (NCT04283461)</td>
   </tr>
   <tr>
    <td align="left">Ad5-nCoV</td>
    <td align="left">Adenovirus type 5 vector that expresses S protein</td>
    <td align="left">CanSino Biologicals</td>
    <td align="left">Phase I (NCT04313127)</td>
   </tr>
   <tr>
    <td align="left">INO-4800</td>
    <td align="left">DNA plasmid encoding S protein delivered by electroporation</td>
    <td align="left">Inovio Pharmaceuticals</td>
    <td align="left">Phase I (NCT04336410)</td>
   </tr>
   <tr>
    <td align="left">LV-SMENP-DC</td>
    <td align="left">DCs modified with the lentiviral vector</td>
    <td align="left">Shenzhen Geno-Immune</td>
    <td align="left">Phase I (NCT04276896)</td>
   </tr>
   <tr>
    <td align="left"/>
    <td align="left">expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs</td>
    <td align="left">Medical Institute</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Pathogen-specific aAPC</td>
    <td align="left">aAPCs modified with the lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td>
    <td align="left">Shenzhen Geno-Immune Medical Institute</td>
    <td align="left">Phase I (NCT04299724)</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
